Skip to main content

NEWSBRIEF: Strong Life-Sciences Growth Buoys Bruker Daltonics Bottom Line

NEW YORK, May 6 - Bruker Daltonics today reported that strong first-quarter growth in its life-sciences business helped boost total revenue despite static or declining performance from other units.


Total revenue in the period ended March 31 grew to $25.7 million from $21.9 million one year ago. Of the company's total product revenues, life science systems accounted for 76 percent, up from 70 percent a year ago, Bruker said. Its substance-detection and aftermarket revenues represent 8 percent and 16 percent of product revenues this year, respectively, compared with 8 percent and 22 percent year over year.


R&D spending in the first quarter 2002 remained relatively flat at $4.5 million compared with $4.6 million reported during the same period one year ago. Total first-quarter costs and operating expenses, though, grew to $24.4 million from $21.2 million year over year.


Bruker also reported a dip in first-quarter net income to $941,000, or $.02 per share, compared with $945,000, or $.02 per share, in the first quarter 2001.


The company said it had $66.8 million in cash and short-term investments as of March 31, a slight drop from the $70.1 million it had as of Dec. 31, 2001.


For more information, click here.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.